COMMENTARY

COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy

Andrew Wolf, MD, MS, and Enrique Alvarez, MD, PhD

Neurology: Clinical Practice August 2021 vol. 11 no. 4 358-361 doi:10.1212/CPJ.0000000000001088

Abstract

The COVID-19 pandemic has resulted in challenges for the practice of neurology. One major concern is how to best manage patients with multiple sclerosis (MS) who are on disease-modifying therapies (DMTs). DMTs frequently have immunosuppressive properties that both increase the risk for COVID-19 and potentially reduce the immunologic response to vaccination in a group already vulnerable to infection due to neurologic deficits. Here, we review early data on COVID-19 outcomes in patients with MS and discuss what is known about vaccine effectiveness in those on anti-CD20 and sphingosine-1-phosphate receptor agents, which are proposed to have attenuating effects based on their mechanisms of action. In addition, we provide recommendations to best use novel COVID-19 vaccines in this population and highlight what information may better inform vaccine strategies in the future.

COVID-19 is a major public health challenge that has resulted in over 2 million deaths worldwide, in addition to extensive economic and social harms. Vaccination for the causative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has emerged as a critical mechanism to prevent COVID-19. In this context, there are unique considerations for patients with multiple sclerosis (MS), particularly those patients who are on immunosuppressive disease-modifying therapies (DMT) that may heighten risk for infection, worsen clinical outcomes from infection, and limit responsiveness to vaccines. Here, we discuss considerations for COVID-19 vaccination in patients with MS on DMT, as well as recommendations for vaccination planning in this vulnerable population.

Discussion

Patients with MS are at heightened risk of infections, particularly urinary and pulmonary infections. Furthermore, patients with MS are at heightened risk for severe infections (defined by hospitalization) than patients with other autoimmune conditions, which may reflect the contributions of neurologic deficits from MS (e.g., bladder dysfunction and dysphagia). Immunomodulatory DMTs, such as glatiramer acetate and interferons, do little to increase the risk beyond this baseline, as seen in their respective clinical trials and real world experience. However, immunosuppressive DMTs (particularly anti-CD20s) exacerbate the risk of infection. In the subpopulation treated with anti-CD20 DMT, male sex and time on rituximab increase the infection risk, but higher disability is a key factor. Although knowledge is evolving, these risks appear to extend to COVID-19. Risk for severe COVID-19 in the MuSC-
19 registry (defined as pneumonia, hospitalization, or death) was higher for those patients with MS using anti-CD20 DMT. Older age, longer disease course, higher disability, progressive disease, and the presence of comorbidities were also associated with severe COVID-19 infection. Preliminary data from the MS Global Data Sharing Initiative also suggested that use of anti-CD20 drugs is associated with 1.5× more hospitalizations, 2.5× more intensive care admissions, and 3× more use of mechanical ventilation compared with other DMTs (Simpson ECTRIMS 2020). However, the COVISEP registry data did not show an association between COVID-19 outcomes and DMT. Taken together, this suggests that patients with MS, especially in certain groups, may be at increased risk for infection and for poor outcomes, further emphasizing the need for effective vaccination.

Dozens of COVID-19 vaccines are in clinical use or development worldwide; 2 vaccines are currently being administered in the United States under emergency use authorization granted by the FDA. These vaccines, BNT162b2 (Pfizer, New York, NY, and BioNTech, Mainz, Germany) and messenger RNA (mRNA)-1273 (Moderna, Cambridge, MA), use lipid nanoparticle–encapsulated mRNA to encode S-2P antigen (modified prefusion conformation of the full-length spike protein). The spike protein is critical for cellular entry of SARS-CoV-2, and these vaccines have demonstrated about 95% protection against symptomatic COVID-19 infection over a 2-month period. Additional candidates are in phase 3 trials in the United States; some of the other vaccines (notably Oxford-AstraZeneca approved in the United Kingdom) use a novel nonreplicating adenovirus vector. DMTs may affect the immunologic responsiveness to any vaccination because they treat MS by modulating/suppressing the immune system. That said, the extent to which any specific DMT may have an impact on COVID-19 vaccine responsiveness is not known. Current data on the efficacy of vaccines in patients with MS on immunosuppressive DMT are limited to traditional vaccine platforms and not the novel mRNA or adenovirus platforms at the forefront of the COVID-19 vaccine programs. With this limitation, there are reasonable concerns about how effective any of the COVID-19 vaccines may be in patients with MS on DMTs.

A full review of vaccines in patients with MS is beyond our scope (Ciotti et al.16). However, completed vaccine studies provide insights regarding if DMTs may affect the efficacy of COVID-19 vaccines. COVID-19 infection induces response in the innate immune system and the adaptive immune system (i.e., antigen-specific cytotoxic T cells directed against the virus and adaptive B-cell response with ultimate production of novel antibodies). Higher ratios of IgG antibodies targeting S1 or receptor-binding domains of the spike protein compared with the nucleocapsid protein were associated with milder illness indicating potential importance for specific antibodies; however, the overall antibody response was considered insufficient to predict clinical outcome.11 Notably, patients with X-linked hypogammaglobulinemia, in addition to most patients with iatrogenic B-cell depletion, can recover from COVID-19 infection, indicating that although B cells may be important in the response to infection, they are not strictly necessary for recovery. There is activation of virus-specific CD4+ and CD8+ T cells in response to BNT162b1, indicating that at least with mRNA-based vaccines, the protective response may be multifactorial.13

The potential for B cell–depleting therapies to attenuate vaccine response is a concern due to their direct effect on humoral immunity and the role of B cells in antigen presentation. This is concordant with concerns about serologic conversion following COVID-19 infection. We are aware of 9 cases of patients with MS who were on anti-CD20 DMT with documented COVID-19 by PCR, but negative serologic testing. That said, the portion of patients, if any, who do seroconvert from infection is not known, and how any degree of baseline hypogammaglobulinemia affects this process is similarly uncertain. Broadly, the recent VELOCIT trial demonstrated reduced levels of vaccine (tetanus toxoid, pneumococcal 13, and influenza) responsiveness and protection, as well as impaired humoral response to stimulatory antigen keyhole limpet hemocyanin, in patients with MS on ocrelizumab. There are no specific data on vaccine responsiveness in patients with MS on rituximab or ofatumumab; the literature from rheumatoid arthritis suggests that rituximab decreases responsiveness similarly.19

The other class of medications concerning for impairing vaccine responsiveness is sphingosine-1-phosphate receptor modulators, which suppress lymphocyte egress from lymph nodes. In a placebo-controlled trial, patients on fingolimod were significantly less likely to respond to influenza and tetanus toxoid vaccines, although the majority still did mount an appropriate response. An additional study evaluating response to influenza vaccination in patients on fingolimod demonstrated reduced response rates when compared with patients not on DMT; in addition to those on glatiramer acetate or interferon beta (neither of which was different from control). Like B cell–depleting therapies, fingolimod may prevent seroconversion.22 There are limited data on siponimod with 1 placebo-controlled study demonstrating reduced responsiveness to vaccination and no published data on ozanimod.23

Conclusions

Widely available and effective vaccination for COVID-19 is an exciting prospect. Although the first FDA-authorized vaccines were given December 2020, the logistics of administration remain challenging. Widespread vaccination may not occur until late 2021. This poses critical questions for patients on or considering initiation of DMT.

For stable patients, continuing current DMT is recommended. Although there is concern that outcomes may be worse and that vaccination may be less effective while on some DMTs, stopping or switching DMT leads to
considerable logistical challenges and may lead to rebound disease activity (e.g., for fingolimod). As there are data that the therapeutic effects of rituximab can extend for months beyond the timing of humoral immune reconstitution, it may be possible to extend the dosing interval to create a window to administer the COVID-19 vaccine and allow for immunologic response. To maximize the immunologic response, it is suggested by the Canadian Network of MS Clinics (cnms.ca/Covid19VaccineGuidance) to wait 4 weeks after the 2nd mRNA vaccine dose for new or repeat infusion of anti-CD20 DMT. For patients already on anti-CD20 DMT, waiting 12 weeks (as in the VELOCE study) after infusion to start the vaccination process is recommended. It has also been proposed to delay vaccination until B-cell reconstitution or toward the end of an infusion cycle, but the risks of contracting COVID-19 need to be considered.

For patients who have not started DMT, considerations for DMT include the expected impact on vaccine efficacy and what other treatment options are available to control the patient’s MS. If possible, a DMT start could be delayed. The prescribing information for ocrelizumab recommends that if possible, to vaccinate with nonlive vaccines 2 weeks before initiation of treatment (Genentech 2017). As above, it is reasonable to extend this interval to 4 weeks following the second dose of a COVID-19 mRNA vaccine. In addition, a bridging strategy could be used by temporarily choosing another DMT. Natalizumab (expected to have minimal impact on COVID-19 vaccine efficacy) is an alternative and could be used in the short-term, even in patients who are JC virus positive. Glatiramer acetate, interferon beta, and dimethyl fumarate are predicted to have relatively minimal impact on COVID-19 vaccination responsiveness and may be more frequently used.

Further characterizing specific vaccine responses with antibody titers and T-cell responses in patients on specific DMTs, in addition to clinical outcome data, will be useful in guiding how to treat and vaccinate patients with MS during the COVID-19 pandemic and into the future. It is recommended that despite uncertainty about vaccination effectiveness, all patients with MS without other contraindications receive a COVID-19 vaccine and follow the AAN vaccine guidelines. Long-term, more knowledge is needed about the factors that increase infection rates and how to mitigate them when possible. A comprehensive strategy around choosing how and when (or not) to treat patients with DMTs as well as developing a vaccination strategy for COVID-19 and other preventable infections in patients with MS is worthy of further investigation.

Study Funding
No targeted funding reported.

Disclosure
A. Wolf reports no disclosures relevant to the manuscript. E. Alvarez has consulted with Actelion/Janssen, Alexion, Bayer, Biogen, Celgene/BMS, EMD Serono/Merck, Genentech/Roche, Genzyme, Novartis, Sanoﬁ, and TG Therapeutics and research support from Biogen, Genentech/Roche, Novartis, TG Therapeutics, Patient-Centered Outcomes Research Initiative, National Multiple Sclerosis Society, NIH, and Rocky Mountain MS Center. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.

Publication History
Received by Neurology: Clinical Practice January 25, 2021. Accepted in final form March 18, 2021.

Appendix Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Wolf, MD, MS</td>
<td>Department of Neurology, University of Colorado School of Medicine, Aurora, CO</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data</td>
</tr>
<tr>
<td>Enrique Alvarez, MD, PhD</td>
<td>Department of Neurology, University of Colorado School of Medicine, Aurora, CO</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data</td>
</tr>
</tbody>
</table>

References


Share Your Insights, Expertise, and Experiences

- How are you employing drugs and devices in your field?
- What ethical challenges do you face?
- Do you have a case report that is illustrative of a clinical challenge?
- What challenges have you faced or successes have you enjoyed in bringing greater efficiency to your practice?

Deliver a high-quality, peer-reviewed message to your colleagues in practice, submit your paper at NPub.org/NCP/submit.
COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy
Andrew Wolf and Enrique Alvarez

Neurol Clin Pract 2021;11:358-361 Published Online before print April 14, 2021
DOI 10.1212/CPJ.0000000000001088

This information is current as of April 14, 2021

Updated Information & Services
including high resolution figures, can be found at:
http://cp.neurology.org/content/11/4/358.full.html

References
This article cites 25 articles, 6 of which you can access for free at:
http://cp.neurology.org/content/11/4/358.full.html##ref-list-1

Citations
This article has been cited by 2 HighWire-hosted articles:
http://cp.neurology.org/content/11/4/358.full.html##otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Clinical Neurology
http://cp.neurology.org/cgi/collection/all_clinical_neurology
All Demyelinating disease (CNS)
http://cp.neurology.org/cgi/collection/all_demyelinating_disease_cns
All Immunology
http://cp.neurology.org/cgi/collection/all_immunology
All Infections
http://cp.neurology.org/cgi/collection/all_infections
COVID-19
http://cp.neurology.org/cgi/collection/covid_19
Multiple sclerosis
http://cp.neurology.org/cgi/collection/multiple_sclerosis

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://cp.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://cp.neurology.org/misc/addir.xhtml#reprintsus

Neurol Clin Pract is an official journal of the American Academy of Neurology. Published continuously since 2011, it is now a bimonthly with 6 issues per year. Copyright © 2021 American Academy of Neurology. All rights reserved. Print ISSN: 2163-0402. Online ISSN: 2163-0933.